Dermata Therapeutics (DRMA) Competitors $0.73 +0.02 (+2.68%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.72 -0.01 (-1.92%) As of 04/17/2025 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DRMA vs. ENLV, PMN, RNXT, QTTB, GRCE, LSB, JATT, RLYB, ANVS, and SNYRShould you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include Enlivex Therapeutics (ENLV), ProMIS Neurosciences (PMN), RenovoRx (RNXT), Q32 Bio (QTTB), Grace Therapeutics (GRCE), Lakeshore Biopharma (LSB), JATT Acquisition (JATT), Rallybio (RLYB), Annovis Bio (ANVS), and Synergy CHC Corp. (Uplisting) (SNYR). These companies are all part of the "pharmaceutical products" industry. Dermata Therapeutics vs. Enlivex Therapeutics ProMIS Neurosciences RenovoRx Q32 Bio Grace Therapeutics Lakeshore Biopharma JATT Acquisition Rallybio Annovis Bio Synergy CHC Corp. (Uplisting) Dermata Therapeutics (NASDAQ:DRMA) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, community ranking, analyst recommendations, dividends, earnings and institutional ownership. Do institutionals & insiders have more ownership in DRMA or ENLV? 8.7% of Dermata Therapeutics shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 9.4% of Dermata Therapeutics shares are owned by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer DRMA or ENLV? Enlivex Therapeutics received 54 more outperform votes than Dermata Therapeutics when rated by MarketBeat users. Likewise, 80.82% of users gave Enlivex Therapeutics an outperform vote while only 50.00% of users gave Dermata Therapeutics an outperform vote. CompanyUnderperformOutperformDermata TherapeuticsOutperform Votes550.00% Underperform Votes550.00% Enlivex TherapeuticsOutperform Votes5980.82% Underperform Votes1419.18% Which has stronger valuation and earnings, DRMA or ENLV? Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDermata TherapeuticsN/AN/A-$7.80M-$16.41-0.04Enlivex TherapeuticsN/AN/A-$29.07M-$0.73-1.18 Is DRMA or ENLV more profitable? Enlivex Therapeutics' return on equity of -67.57% beat Dermata Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dermata TherapeuticsN/A -247.39% -179.72% Enlivex Therapeutics N/A -67.57%-58.45% Does the media favor DRMA or ENLV? In the previous week, Dermata Therapeutics had 4 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 5 mentions for Dermata Therapeutics and 1 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 1.00 beat Dermata Therapeutics' score of 0.13 indicating that Enlivex Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Dermata Therapeutics Neutral Enlivex Therapeutics Positive Do analysts prefer DRMA or ENLV? Dermata Therapeutics currently has a consensus target price of $6.00, indicating a potential upside of 723.05%. Enlivex Therapeutics has a consensus target price of $10.00, indicating a potential upside of 1,056.07%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than Dermata Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dermata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has more volatility & risk, DRMA or ENLV? Dermata Therapeutics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. SummaryEnlivex Therapeutics beats Dermata Therapeutics on 12 of the 16 factors compared between the two stocks. Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRMA vs. The Competition Export to ExcelMetricDermata TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.40M$6.46B$5.32B$7.35BDividend YieldN/A3.21%5.47%4.31%P/E Ratio-0.046.9521.9417.82Price / SalesN/A231.01380.9497.72Price / CashN/A65.6738.3134.64Price / Book0.035.936.453.98Net Income-$7.80M$143.22M$3.22B$247.81M7 Day Performance-9.78%4.28%5.85%3.19%1 Month Performance-38.22%-13.11%-9.58%-7.70%1 Year Performance-84.86%-8.51%11.85%1.49% Dermata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRMADermata Therapeutics1.8796 of 5 stars$0.73+2.7%$6.00+723.0%-85.3%$4.40MN/A-0.048Short Interest ↑News CoveragePositive NewsENLVEnlivex Therapeutics3.2684 of 5 stars$0.89+0.2%$10.00+1,023.6%-34.5%$19.05MN/A-0.9170Short Interest ↓PMNProMIS Neurosciences2.8592 of 5 stars$0.58-5.1%$6.00+929.7%-67.4%$19.05MN/A-5.835RNXTRenovoRx2.0042 of 5 stars$0.79-10.4%$6.00+659.5%-12.8%$18.96M$43,000.00-1.396Short Interest ↑News CoverageGap DownHigh Trading VolumeQTTBQ32 Bio1.7965 of 5 stars$1.53-6.7%$24.71+1,515.3%-90.6%$18.66M$-6,651,000.00-0.1139News CoverageGRCEGrace TherapeuticsN/A$1.80-10.0%$12.00+566.7%N/A$18.25MN/A-1.55N/AGap DownLSBLakeshore Biopharma0.5113 of 5 stars$1.95-6.7%N/AN/A$18.15M$672.27M0.00773Short Interest ↑Gap UpHigh Trading VolumeJATTJATT AcquisitionN/A$1.03-5.1%N/A-62.8%$17.77MN/A0.003High Trading VolumeRLYBRallybio1.7685 of 5 stars$0.42-5.6%$9.75+2,194.7%-85.8%$17.68M$636,000.00-0.2740Analyst ForecastGap DownANVSAnnovis Bio1.474 of 5 stars$1.24-5.7%$37.00+2,896.0%-87.7%$17.58MN/A-0.283Gap UpSNYRSynergy CHC Corp. (Uplisting)2.8744 of 5 stars$2.03-11.7%$10.00+392.6%N/A$17.40M$34.83M0.0040Lockup ExpirationNews CoverageNegative NewsGap DownHigh Trading Volume Related Companies and Tools Related Companies ENLV Competitors PMN Competitors RNXT Competitors QTTB Competitors GRCE Competitors LSB Competitors JATT Competitors RLYB Competitors ANVS Competitors SNYR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRMA) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DRMA Stock Free DRMA Stock Alerts